Section 4: Implementation and Capacity (35 Points)
This section addresses the Implementation and Capacity evaluation criteria (35 points total):
- C.1 Quality and Feasibility of Work Plan (20 points) - Milestones, timeline, deliverables, risk management
- C.2 Team and Resources (10 points) - Expertise, track record, organizational capacity
- C.3 Budget and Cost-Effectiveness (5 points) - Appropriate allocation, ROI, co-financing
C.1 Quality and Feasibility of Work Plan (20 Points)
Project Objectives (Aligned with EPIC-X Program Duration)
Timeline: 6 months (April 1 - September 30, 2026)
Primary Objectives:
-
US Market Entry via FDA 510(k) Clearance
- Target: FDA clearance obtained by Q4 2026
- Interim milestone: Pre-submission meeting completed Q2 2026, submission filed Q3 2026
-
Series A Fundraising (EUR 5-10M)
- Target: Term sheet signed by Q3 2026, funding closed Q4 2026
- Interim milestone: 20+ investor meetings conducted, 2+ term sheets received
-
European Hospital Partnerships (Germany, France, Italy)
- Target: 3-5 pilot contracts signed by Q3 2026
- Interim milestone: 15+ C-suite decision-maker meetings, pilot proposals submitted
-
Women Leadership Visibility Platform
- Target: 5+ conference talks delivered, 3+ media features published by Q3 2026
- Interim milestone: Conference speaking engagements secured, PR strategy launched
12-Month Work Plan (Q2 2026 - Q1 2027)
Quarter 1 (April - June 2026)
Month 1 (April 2026):
| Week | Objective | Key Activities | Deliverables | Owner | Coaching Module |
|---|---|---|---|---|---|
| 1-2 | FDA Pre-Submission Prep | - Kick-off meeting with FDA regulatory coach - Predicate device analysis - Clinical data package review | - FDA pre-submission meeting deck (draft v1.0) | Andy + Regulatory Team | Module 1 (Day 1-2) |
| 2-3 | Series A Investor Targeting | - Kick-off with fundraising coach - VC target list creation (20+ funds) - Pitch deck review session | - Investor target list - Pitch deck v2.0 (draft) | Andy + CFO | Module 2 (Day 1-2) |
| 3-4 | European Market Research | - Germany/France/Italy hospital landscape analysis - Procurement process research - Pilot proposal template creation | - Market entry strategy doc (Germany/France/Italy) | Commercial Team | Module 3 (Day 1) |
| 4 | PR Strategy Launch | - Kick-off with PR coach - Conference target list creation - LinkedIn content calendar | - 12-month PR calendar - Conference applications submitted | Andy + Marketing | Module 4 (Day 1) |
Month 2 (May 2026):
| Week | Objective | Key Activities | Deliverables | Owner | Coaching Module |
|---|---|---|---|---|---|
| 5-6 | FDA Pre-Submission Meeting | - Final pre-submission deck preparation - Mock FDA Q&A session with coach - FDA pre-submission meeting | - FDA meeting minutes - FDA feedback incorporation plan | Andy + Regulatory | Module 1 (Day 3-4) |
| 6-7 | Investor Outreach (Round 1) | - First 10 investor meetings - Pitch refinement based on feedback - Financial model finalization | - Investor meeting logs - Pitch deck v2.1 - 3-year financial model | Andy + CFO | Module 2 (Day 3-4) |
| 7-8 | European C-Suite Meetings | - Germany: Charité Berlin, University Hospital Heidelberg meetings - Pilot proposal presentations | - 5+ C-suite meetings held - Pilot proposals submitted (Germany) | Commercial Team | Module 3 (Day 2-3) |
| 8 | Conference Speaking (First Talk) | - First conference talk delivered (e.g., EIT Health Summit) - LinkedIn post-talk content | - Conference talk delivered - LinkedIn engagement metrics | Andy | Module 4 (Day 2) |
Month 3 (June 2026):
| Week | Objective | Key Activities | Deliverables | Owner | Coaching Module |
|---|---|---|---|---|---|
| 9-10 | FDA 510(k) Submission Prep | - Clinical data package finalization - Labeling and indications review - QSR compliance audit | - 510(k) submission package (95% complete) | Regulatory Team | Module 1 (Day 5) |
| 10-11 | Investor Outreach (Round 2) | - Second 10 investor meetings - Term sheet negotiation coaching - Due diligence preparation | - 20+ investor meetings total - 1-2 term sheets received | Andy + CFO | Module 2 (Day 5-6) |
| 11-12 | European Pilot Negotiations | - France: AP-HP network meetings - Italy: Lombardy regional health system meetings - Contract negotiation | - Pilot contract negotiations ongoing (France/Italy) | Commercial Team | Module 3 (Day 4) |
| 12 | Media Features (First Article) | - First media feature published (e.g., TechCrunch Europe) - Press kit finalization | - Media article published - Press kit | Andy + PR Agency | Module 4 (Day 3) |
Q1 Summary Deliverables:
- ✅ FDA pre-submission meeting completed, feedback incorporated
- ✅ 20+ investor meetings conducted, 1-2 term sheets received
- ✅ 10-15 C-suite meetings (Germany/France/Italy)
- ✅ 1-2 conference talks delivered, 1 media feature published
Quarter 2 (July - September 2026)
Month 4 (July 2026):
| Week | Objective | Key Activities | Deliverables | Owner |
|---|---|---|---|---|
| 13-14 | FDA 510(k) Submission | - Final submission package review - FDA submission portal upload - Submission confirmation | - FDA 510(k) submitted - FDA acknowledgment letter | Regulatory Team |
| 14-15 | Series A Term Sheet Negotiation | - Term sheet review with coach - Valuation negotiation - Due diligence coordination | - Term sheet signed (target) - Due diligence checklist | Andy + CFO |
| 15-16 | European Pilot Contract Signatures | - Germany pilot contract finalization - France pilot contract finalization | - 1-2 pilot contracts signed | Commercial Team |
| 16 | Conference Speaking (Second Talk) | - Second conference talk (e.g., HIMSS Europe) - Networking with hospital decision-makers | - Conference talk delivered | Andy |
Month 5 (August 2026):
| Week | Objective | Key Activities | Deliverables | Owner |
|---|---|---|---|---|
| 17-18 | Series A Due Diligence | - Investor due diligence support - Legal documentation review - Cap table preparation | - Due diligence materials provided - Legal docs in progress | CFO + Legal |
| 18-19 | European Pilot Implementation | - Germany pilot kick-off - France pilot kick-off - Training for hospital staff | - Pilot implementations started (2 sites) | Clinical Team |
| 19-20 | Mentorship Program Launch | - Women in deep-tech mentorship program design - Mentee recruitment (10 mentees) | - Mentorship program launched | Andy |
Month 6 (September 2026):
| Week | Objective | Key Activities | Deliverables | Owner |
|---|---|---|---|---|
| 21-22 | Series A Funding Close | - Final legal negotiations - Wire transfer coordination - Cap table update | - Series A closed (EUR 5-10M) - Funding announcement | Andy + CFO |
| 22-23 | European Contract Expansion | - Italy pilot contract finalization - Additional Germany/France pilots | - 3-5 total pilot contracts signed | Commercial Team |
| 23-24 | Thought Leadership (Final Push) | - Conference talks 3-5 delivered - Media features 2-3 published - LinkedIn content series | - 5+ total conference talks - 3+ total media features | Andy |
| 24 | EPIC-X Program Wrap-Up | - Final reporting to EPIC-X - Outcomes documentation - Alumni network engagement | - EPIC-X final report submitted | Andy |
Q2 Summary Deliverables:
- ✅ FDA 510(k) submitted (acknowledgment received)
- ✅ Series A funding closed (EUR 5-10M)
- ✅ 3-5 European pilot contracts signed
- ✅ 5+ conference talks delivered, 3+ media features published
- ✅ Mentorship program launched (10 mentees)
Quarter 3-4 (October 2026 - March 2027): Post-EPIC-X Execution
Month 7-9 (October - December 2026):
- FDA 510(k) review process (FDA response expected Q4 2026)
- Series A capital deployment: Team scaling (10 new hires), US market entry preparation
- European pilot execution and data collection
Month 10-12 (January - March 2027):
- FDA 510(k) clearance (target: Q4 2026 or Q1 2027)
- US hospital pilots (1-2 contracts signed)
- European pilot conversion to full contracts (3-5 sites)
Deliverables Summary (Aligned with EPIC-X 6 Tasks)
| EPIC-X Task | Deliverable | Owner | Deadline | Status Tracking |
|---|---|---|---|---|
| 1. Legal Entity Form (Annex 2) | Corporate documentation, financials | Finance | Dec 19, 2025 | External (Google Docs) |
| 2. Women's Leadership Declaration (Annex 3) | Ownership/board evidence | Andy/HR | Dec 19, 2025 | External (Google Docs) |
| 3. Business Coaching Plan (Annex 4) | 4-module coaching plan | Andy | Dec 19, 2025 | Section 5 of this application |
| 4. Market Fit & Investment Docs | Hospital contracts, CDTI grant, revenue data | Commercial/Finance | Dec 19, 2025 | Section 3 + supporting docs |
| 5. Online Application Form | Complete application (6 sections) | Andy | Jan 5, 2026 | This document (Sections 1-6) |
| 6. 2-Minute Pitch Video | Video pitch (Andy presenting) | Andy/Marketing | Jan 5, 2026 | YouTube/Vimeo link |
Risk Management
Risk Register (Top 5 Risks):
| Risk ID | Risk Description | Likelihood | Impact | Mitigation Strategy | Contingency Plan | Owner |
|---|---|---|---|---|---|---|
| R1 | FDA 510(k) delays (review >6 months) | Medium | High | - Early pre-submission meeting (Q2 2026) - Comprehensive clinical data package - EPIC-X coaching (Module 1) | - Alternative: EU-first expansion while awaiting FDA - Accelerate European revenue to offset US delay | Regulatory |
| R2 | Series A fundraising shortfall (<EUR 5M) | Low-Medium | High | - 20+ investor pipeline (diversification) - Strong traction (EUR 192K won, 7 studies) - EPIC-X coaching (Module 2) | - Bridge financing from existing CDTI grant - Extend runway via cost controls - Consider EUR 3-5M raise if market conditions weak | CFO |
| R3 | European pilot delays (procurement bureaucracy) | Medium | Medium | - Early C-suite engagement (Q2 2026) - Procurement process coaching (Module 3) - Flexible pilot contract templates | - Focus on fast-moving hospitals - Pivot to private clinics if public system too slow - Leverage existing Spain relationships for warm intros | Commercial |
| R4 | Key personnel loss (CEO, Head MDS, Regulatory) | Low | High | - Competitive compensation (Series A proceeds) - Stock option retention incentives - Strong company culture and mission alignment | - Succession planning for critical roles - External recruitment via VC network - Interim consultants for specialized roles | Andy/HR |
| R5 | Competitive entry (large med device incumbents) | Medium | Medium | - Regulatory moat (CE MDR Class IIb, FDA 510(k)) - Clinical validation (7 studies, 6 publications) - Hospital relationships (switching costs) | - Accelerate product development (expand to 400+ conditions) - Deepen hospital integrations (lock-in via workflows) - Strategic partnerships with pharma | Andy/Product |
Risk Monitoring:
- Monthly risk review meetings (Andy + leadership team)
- Quarterly risk report to board
- Escalation protocol for high-impact risks materializing
C.2 Team and Resources (10 Points)
Leadership Team: Proven Track Record
CEO & Co-Founder: Sheyla Andina Aguilar (Andy Aguilar)
Background (Full biography in Section 6):
- Education: B.B.A. from Tecnológico de Monterrey (2011-2016), Marketing (UPV/EHU), Exchange (University of Mississippi)
- Recognition: Forbes 30 Under 30, Forbes 100 Most Creative Individuals in Business
- Entrepreneurial Experience: 4 ventures before Legit.Health (Gïk Live!, LegeBot, Hola Plates, News-Worth Creation)
- Legit.Health Tenure: CEO since founding (September 2017, 8+ years)
Key Achievements:
- Secured CE MDR Class IIb certification (2023) - highest regulatory bar for medical AI
- Won EUR 2.5M CDTI Sello de Excelencia grant (2024)
- Established 7 clinical validation studies with 1000+ patients
- Scaled team from 3 founders to 31 FTEs
- Generated EUR 192K+ in won contracts
Responsibilities:
- Strategic direction and company vision
- Fundraising and investor relations (Series A target: EUR 5-10M)
- Partnership development (hospitals, pharmaceutical companies)
- Women leadership visibility and thought leadership
Management Team
| Role | Name | Background | Key Achievements |
|---|---|---|---|
| CTO (Chief Technology Officer) | [UPDATE: Name] | [UPDATE: Education, experience] | - Technical architecture design - Engineering team leadership (X FTEs) |
| Head of Medical Data Science | [UPDATE: Name] | PhD in [AI/ML/Computer Vision], [X] years experience | - AI model development (239 conditions) - Clinical validation studies |
| Head of Regulatory Affairs | [UPDATE: Name] | Regulatory affairs experience in medical devices | - CE MDR certification leadership - FDA 510(k) strategy |
| Head of Commercial | [UPDATE: Name] | Healthcare sales/BD background | - EUR 695K+ contracts closed (2020-2025) - Hospital partnership pipeline |
| CFO (Chief Financial Officer) | [UPDATE: Name] | Finance background, startup experience | - CDTI grant management - Series A fundraising preparation |
Board of Advisors (if applicable):
| Name | Role/Expertise | Affiliation | Contribution to Legit.Health |
|---|---|---|---|
| [UPDATE: Name] | Dermatology clinical expert | [Hospital/University] | Clinical validation guidance, hospital introductions |
| [UPDATE: Name] | Regulatory affairs (FDA/EMA) | [Consulting firm] | Regulatory strategy for US/EU markets |
| [UPDATE: Name] | Healthcare VC investor | [VC fund] | Fundraising coaching, investor introductions |
Organizational Capacity
Team Composition (31 FTEs, December 2024)
| Department | FTEs | Key Roles | Women % |
|---|---|---|---|
| Medical Data Science | [UPDATE: Count] | ML Engineers, Data Scientists, Computer Vision Researchers | [UPDATE: %] |
| Software Engineering | [UPDATE: Count] | Full-stack developers, DevOps, QA | [UPDATE: %] |
| Regulatory & Quality | [UPDATE: Count] | Regulatory Affairs Managers, QA Specialists | [UPDATE: %] |
| Clinical | [UPDATE: Count] | Clinical Research Coordinators, Medical Advisors | [UPDATE: %] |
| Commercial | [UPDATE: Count] | Sales, Business Development, Customer Success | [UPDATE: %] |
| Finance & Operations | [UPDATE: Count] | Finance, HR, Legal, IT | [UPDATE: %] |
| TOTAL | 31 | [UPDATE: Overall %] |
Post-Series A Hiring Plan (Q4 2026 - Q1 2027):
| Role | Count | Rationale | Timeline |
|---|---|---|---|
| Medical Data Scientists | +2 | US market models (FDA-specific validation), rare disease focus | Q4 2026 |
| Commercial (US) | +2 | US hospital sales, reimbursement strategy | Q1 2027 |
| Commercial (EU) | +2 | Germany/France/Italy market development | Q4 2026 |
| Regulatory Affairs (US) | +1 | FDA post-market surveillance, US compliance | Q1 2027 |
| Software Engineers | +2 | US EHR integrations (Epic, Cerner), scalability | Q4 2026 |
| Clinical Study Coordinators | +1 | US clinical studies coordination | Q1 2027 |
| TOTAL NEW HIRES | +10 | Q4 2026 - Q1 2027 |
Organizational Certifications
| Certification | Issuing Body | Certificate # | Issue Date | Validity | Significance |
|---|---|---|---|---|---|
| ISO 13485:2016 (QMS) | BSI (British Standards Institution) | [UPDATE: Certificate #] | [Year] | [Renewal date] | Quality Management System for medical devices - prerequisite for CE/FDA |
| CE MDR Class IIb | BSI (Notified Body 2797) | [UPDATE: Certificate #] | 2023 | [Renewal: 2028] | EU Medical Device Regulation conformity - highest AI/ML device class |
| GDPR Compliance | Internal audit + legal review | N/A (ongoing) | 2018 (GDPR effective) | Ongoing | EU data protection compliance for patient data |
Track Record: Demonstrated Execution Capability
8+ Years of Continuous Operation (September 2017 - present):
- Founded during early wave of medical AI development (pre-GPT era)
- Survived COVID-19 pandemic disruption (2020-2021)
- Pivoted from B2C to B2B2C model based on market feedback (demonstrating adaptability)
Regulatory Clearances (4 markets):
- CE MDR Class IIb (EU) - 2023
- AEMPS (Spain) - 2021 (ES-MD2021-0027)
- MHRA (UK) - [Year]
- ANVISA (Brazil) - [Year]
- FDA 510(k) (US) - In progress (2025-2026)
Clinical Validation (7 studies, 1000+ patients):
- Consistent execution of prospective clinical studies across multiple hospitals
- Published 6+ peer-reviewed papers in dermatology and AI journals
- Established credibility with pharmaceutical companies (Boehringer Ingelheim n=1000 study)
Fundraising Success:
- CDTI Sello de Excelencia grant (EUR 2.5M) - competitive government validation
- Managed non-dilutive financing to date (maintaining founder control)
Commercial Traction:
- EUR 695K+ in won contracts (Janssen EUR 220K+, Sagimet EUR 156K, Boehringer EUR 127K, historical contracts EUR 192K+)
- Diverse customer base (hospitals, pharmaceutical companies, teledermatology platforms)
- Proven ability to close enterprise sales cycles (6-12 months), including multi-year pharma partnerships
C.3 Budget and Cost-Effectiveness (5 Points)
EUR 60,000 Grant Allocation
Budget Breakdown:
| Category | Subcategory | Amount | % of Grant | Justification | Expected ROI |
|---|---|---|---|---|---|
| US Market Entry | FDA regulatory consultants | EUR 10,000 | 16.7% | Expert guidance on 510(k) submission, pre-submission meeting prep | FDA clearance = 330M population access |
| US clinical validation | EUR 5,000 | 8.3% | Bridging studies for FDA requirements | Clinical data package completion | |
| US market research | EUR 3,000 | 5.0% | Hospital landscape analysis, reimbursement pathways | Targeted US sales strategy | |
| Legal (US entity setup) | EUR 2,000 | 3.3% | Delaware C-corp or LLC for US operations | US market operational readiness | |
| FDA 510(k) Submission | Filing fees | EUR 10,000 | 16.7% | FDA user fees (~USD $12,000) | FDA review process initiated |
| Predicate device analysis | EUR 3,000 | 5.0% | Substantial equivalence documentation | 510(k) submission quality | |
| Labeling compliance | EUR 2,000 | 3.3% | US labeling requirements (21 CFR Part 801) | FDA approval likelihood ↑ | |
| European Partnerships | Germany market entry | EUR 5,000 | 8.3% | Market research, pilot proposals, travel to hospital meetings | 2+ pilot contracts (Germany) |
| France market entry | EUR 5,000 | 8.3% | AP-HP procurement research, contract templates | 1-2 pilot contracts (France) | |
| Italy market entry | EUR 3,000 | 5.0% | Regional health system navigation | 1 pilot contract (Italy) | |
| Legal (EU contracts) | EUR 2,000 | 3.3% | Pilot contract review, procurement compliance | Contract risk mitigation | |
| Women Leadership | Conference participation | EUR 4,000 | 6.7% | Travel, registration for 5+ conferences (EIT Health, HIMSS Europe) | Visibility, C-suite networking |
| PR agency retainer | EUR 3,000 | 5.0% | 6-month PR retainer for media outreach (3+ features) | Media visibility, thought leadership | |
| LinkedIn/social media | EUR 2,000 | 3.3% | Content creation, sponsored posts, professional photography | +2,000 followers, brand building | |
| Mentorship program | EUR 1,000 | 1.7% | Platform setup, materials for 10 mentees | Women in deep-tech ecosystem impact | |
| TOTAL | EUR 60,000 | 100% | EUR 250K+ ARR Year 1 (4.2x return) |
Co-Financing (EUR 230,000+)
Legit.Health Cash Contribution:
| Category | Amount | Source | Purpose |
|---|---|---|---|
| Personnel (6 months) | EUR 150,000 | Operating cash | Andy (CEO), Regulatory team, MDS team, Commercial team salaries during EPIC-X program |
| Infrastructure | EUR 30,000 | Operating cash | Cloud computing (AWS), GPU clusters, data storage for US/EU deployments |
| Clinical studies (ongoing) | EUR 50,000 | CDTI grant + revenue | Continued validation studies in Europe (data collection, dermatologist time) |
| TOTAL CASH | EUR 230,000 |
In-Kind Contributions:
- Andy Aguilar time commitment: 25% of CEO time dedicated to EPIC-X coaching and execution (~EUR 40K opportunity cost)
- Office space and equipment (Bilbao headquarters)
- Existing regulatory infrastructure (ISO 13485 QMS, CE MDR compliance processes)
Total Co-Financing: EUR 230,000 cash + EUR 40,000 in-kind = EUR 270,000
Leverage Ratio: EPIC-X EUR 60,000 / Total project EUR 330,000 = 18.2% grant funding, 81.8% co-financing
Return on Investment (ROI)
Direct ROI (12-Month Revenue Impact):
| Investment Category | Grant Amount | Revenue Impact (12 Months) | ROI Multiple |
|---|---|---|---|
| US Market Entry + FDA | EUR 35,000 | EUR 100,000 ARR (2 US hospital pilots) | 2.9x |
| European Partnerships | EUR 15,000 | EUR 150,000 ARR (3-5 EU pilots) | 10x |
| Women Leadership | EUR 10,000 | EUR 0 (indirect: visibility → partnerships) | Indirect |
| TOTAL | EUR 60,000 | EUR 250,000 ARR | 4.2x |
Indirect ROI (Enabled by EPIC-X Coaching):
| Outcome | Value | Coaching Module Attribution | ROI Calculation |
|---|---|---|---|
| Series A Funding | EUR 5-10M | Module 2 (Fundraising, EUR 7,000) | 714-1,429x coaching investment |
| FDA Clearance | EUR 500K+ ARR (2027-2028) | Module 1 (FDA, EUR 5,000) | 100x+ over 2 years |
| EU Market Access | EUR 300K+ ARR (2027) | Module 3 (Partnerships, EUR 5,000) | 60x over 2 years |
| Thought Leadership | 10 mentees launched, 500+ inspired at conferences | Module 4 (Visibility, EUR 3,000) | Ecosystem impact (non-monetizable) |
Total ROI Summary:
- Year 1 Direct Revenue: EUR 250K (4.2x grant)
- Series A Capital Mobilized: EUR 5-10M (83-167x grant)
- 2-Year Cumulative Revenue: EUR 800K+ (13x grant)
- Strategic Value: FDA clearance (330M population access) = incalculable
Cost-Effectiveness Comparison
Alternative Scenarios (without EPIC-X grant):
| Scenario | Cost | Timeline | Outcome | Cost-Effectiveness vs. EPIC-X |
|---|---|---|---|---|
| Hire FDA consultant independently | EUR 50,000 | +6 months | Same FDA clearance, but slower and more expensive | 1.4x more expensive, 6-month delay |
| Fundraising advisor retainer | EUR 30,000 | +3 months | Series A raised, but weaker terms (no EPIC-X coaching) | 4.3x more expensive for Module 2 |
| European BD team expansion | EUR 120,000 (2 FTEs) | +12 months | Same 3-5 pilots, but hiring + onboarding delay | 8x more expensive for Module 3 |
| PR agency annual retainer | EUR 36,000 | 12 months | Similar visibility, but no EPIC-X network access | 12x more expensive for Module 4 |
| TOTAL ALTERNATIVE COST | EUR 236,000 | +6-12 months delay | 3.9x more expensive than EPIC-X |
EPIC-X Value Proposition:
- Coaching efficiency: EUR 20,000 for 20 days of expert coaching (EUR 1,000/day) vs. market rate EUR 2,000-3,000/day for comparable consultants
- Network access: EPIC-X alumni, EIT connections, European Commission visibility = priceless
- Timeline acceleration: 6-month focused program vs. 12-18 month bootstrapped approach
Conclusion: Implementation Readiness & Capacity
Legit.Health demonstrates exceptional implementation readiness and organizational capacity:
✅ Feasible Work Plan (C.1): Detailed 12-month roadmap with quarterly milestones, monthly deliverables, and weekly activities. Risk register addresses top 5 risks with mitigation and contingency plans. Aligned with EPIC-X 6-task deliverables.
✅ Proven Team (C.2): 8+ years track record, 4 regulatory clearances, 7 clinical studies, EUR 192K+ contracts. Leadership team with deep expertise (CEO, CTO, Regulatory, MDS, Commercial). ISO 13485 certified organization.
✅ Cost-Effective Budget (C.3): EUR 60,000 grant allocated across 4 strategic priorities (US 58.3%, EU 25%, Women 16.7%). EUR 270,000 co-financing (4.5x grant). 4.2x direct ROI in Year 1, 83-167x ROI via Series A, 3.9x more cost-effective than alternative approaches.
This combination of detailed planning, organizational excellence, and cost-effectiveness ensures EPIC-X's EUR 60,000 investment will generate maximum impact for both Legit.Health's growth and the broader deep-tech ecosystem.